Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Jochen Utikal, Thomas Eigentler et al.|The Lancet|2020Cited by 242
459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREGMaximilian Haist, Carmen Loquai, Henner Stege et al.|Regular and Young Investigator Award Abstracts|2023Cited by 0